The U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen), an antisense oligonucleotide developed by Ionis Pharmaceuticals, as the first disease-modifying treatment for Alexander disease, a rare and often fatal neurological disorder.
The approval marks a significant milestone for the approximately 500 to 1,000 patients worldwide living with the condition and represents the first therapy to address the underlying cause of the disease rather than simply managing symptoms. It is also the second Ionis-discovered RNA-targeted medicine to be approved, following the success of Spinraza for spinal muscular atrophy.
A Disease Without Previous Treatment Options
Alexander disease is a progressive and fatal leukodystrophy caused by mutations in the GFAP (glial fibrillary acidic protein) gene. The condition leads to the destruction of white matter in the brain, causing severe neurological decline, including developmental delay, seizures, spasticity, and loss of motor function. Most patients with the infantile-onset form do not survive beyond childhood.
Until now, no disease-modifying therapies were available. Treatment has been limited to managing symptoms and providing supportive care.
How Zanvastro Works
Zanvastro is an antisense oligonucleotide, a class of RNA-targeted medicines that work at the genetic level. The drug is designed to target GFAP messenger RNA (mRNA), reducing the production of GFAP protein and thereby decreasing the accumulation of abnormal protein aggregates that drive disease progression.
The therapy is administered via intrathecal injection — delivered directly into the cerebrospinal fluid — every four weeks. The approach is similar to the delivery method used for Spinraza, Ionis's approved therapy for spinal muscular atrophy.
A 'Huge Step Forward' in RNA Medicine
The FDA approval was supported by clinical trial data demonstrating a reduction in GFAP protein levels in cerebrospinal fluid and a stabilisation of clinical symptoms in treated patients. The agency determined that the overall benefit-risk profile was favorable, concluding that the significant unmet need outweighed the risks.
Dr. Francis Collins, a prominent figure in genomics and public health who helped initiate a natural history study for Alexander disease at the National Institutes of Health (NIH), described the approval as "a huge step forward."
"This approval provides an approved medicine for patients with this devastating disease," Ionis Chief Development Officer Dr. Richard Geary said in a statement. "It also expands the potential of RNA-targeted medicines for severe neurologic diseases and underscores Ionis's leadership in RNA-targeted therapeutics."
Implications for the RNA-Targeted Medicine Field
Alexander disease is one of more than 20 genetic conditions for which Ionis has antisense oligonucleotides in development. The company has built its pipeline around the idea that many diseases are caused by the production of toxic proteins or the absence of functional proteins, and that RNA-targeted therapies can address these underlying mechanisms.
The approval of Zanvastro is the latest validation of the approach, which has already produced Spinraza for spinal muscular atrophy and has shown promise in other neurological and genetic conditions.
Looking Ahead
The approval paves the way for expanded access to the therapy, though challenges remain. The treatment is expected to carry a high price tag, a common barrier in rare disease medicine. The company has already made the drug available under an expanded access program, which allowed patients to receive the therapy before formal approval while the clinical trial was ongoing.
For the small community of patients and families affected by Alexander disease, the approval of Zanvastro marks the first time they have a treatment to offer — a significant step forward in a disease that has long been considered untreatable.